SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
FibroBiologics appointed Kathleen Rubins, Ph.D., a retired NASA astronaut and microbiologist, as a Class III director effective July 8, 2026, with assignment to the Audit, Compensation, and Governance committees. Dr. Rubins brings distinguished scientific credentials and has served on the company's Scientific Advisory Board since 2022.
View raw filing on EDGAR →Paycom appointed two directors to its board effective July 8, 2026: Craig E. Boelte, former CFO (retired February 2025), and William Kerber, former CIO (departed 2017). Both individuals bring substantial company history and expertise to the board.
View raw filing on EDGAR →The press release announces the appointment of Ralph (Cody) Kittle to Telesat's Board of Directors as a nominee of MHR Fund Management LLC, succeeding Michael Targoff. This is a discrete governance event involving the appointment of a director to the board. While the release also acknowledges Targoff's departure after 19 years, the principal disclosed action is Kittle's appointment to the board, making this an exec_appointment event. Board composition changes at public companies are material to investors assessing governance and oversight.
View raw filing on EDGAR →The disclosure centers on the appointment of Derek Rush as a director and member of the audit committee on July 2, 2026, increasing the Board to seven members. While the section also mentions an indemnification agreement, the principal disclosed action is the appointment of a person to a board role. This is material to investors as it affects board composition and governance structure.
View raw filing on EDGAR →On July 7, 2026, Bronwyn Barnes, Quinton Hennigh, Hugh Callaghan, and Michael Porter were appointed to the board of directors, with Barnes serving as Chairwoman and Porter chairing both the Audit and Compensation Committees.
View raw filing on EDGAR →The 6-K discloses the appointment of two new independent directors effective July 9, 2026: Mr. King Fui Lee as an independent director and Audit Committee Chairman, and Mr. Ke Zhang as an independent director. While the filing also mentions the departure of two prior independent directors (Ms. Jie Jiao and Mr. Jingchuan Li), the principal disclosed action is the appointment of new board members with detailed biographical information, making this an exec_appointment event. Board composition changes affecting audit oversight are material to investors.
View raw filing on EDGAR →The filing discloses both a departure (Cory Nickel's termination as Senior Vice President and General Manager) and an appointment (John Jamieson's appointment to the same role, effective immediately on July 7, 2026). While both events occurred, the principal disclosed action centers on the appointment of Jamieson to a senior operational role with a salary increase from $193,000 to $205,000. The detailed biographical information and Board approval of compensation changes emphasize the appointment as the primary event. This is material as it involves a change in senior management responsible for operations.
View raw filing on EDGAR →The exhibit announces the appointment of Brian Hartzband as President of U.S. Operations, a named executive role. The disclosure emphasizes his responsibility for leading U.S. growth strategy, commercial operations, and market expansion—a material operational leadership position. The appointment is presented as a strategic milestone supporting the company's North American expansion and long-term growth execution.
View raw filing on EDGAR →The filing discloses the Board's appointment of Alisa Bowen as Chief Executive Officer of FuboTV, effective July 10, 2026, succeeding co-founder David Gandler. While Gandler's departure is also mentioned, the principal disclosed action centers on the appointment of a new CEO—a veteran media executive with extensive experience at Disney, News Corporation, and other major media organizations. This is a material executive leadership transition at a public company.
View raw filing on EDGAR →Haiyan Song was appointed as a new Class III director effective July 9, 2026, bringing cybersecurity and software expertise to strengthen the Board's capabilities. The appointment was accompanied by related board transitions including Greg Nixon's resignation as preferred stock director and Nathaniel Fick's transition from Class III to preferred stock director.
View raw filing on EDGAR →GSK announced the appointment of Roy Jakobs as a Non-Executive Director effective 13 July 2026. The disclosure details his background as CEO of Royal Philips, his independence status, compensation terms (£122,258 annual fee), and share ownership requirements. This is a clear executive appointment to the Board, material to investors assessing governance and leadership composition.
View raw filing on EDGAR →David Kratochvil was appointed as Chief Executive Officer on July 2, 2026, following the resignation of Mike Schmidt. The appointment includes a new employment agreement with a base salary of $180,000 and 100,000 stock units.
View raw filing on EDGAR →Enovix announced the appointment of Dr. Michael Vyvoda as Chief Operating Officer, effective July 29, 2026. The disclosure details his background, compensation package ($440,000 base salary plus 60% bonus target and $4.1 million in RSUs), and severance terms. While the filing includes compensatory arrangements, the principal disclosed action is the appointment of a named executive officer to a C-suite role, making exec_appointment the most salient classification.
View raw filing on EDGAR →The disclosure centers on two executive transitions: David Pirman's promotion to Executive Vice President and Head of Discovery (a clear appointment to a senior role), and Bruce Car's transition from Chief Scientific Officer to Chief Innovation Officer (a role change with reduced compensation). While Car's departure from the CSO role is mentioned, the filing emphasizes the new appointments and organizational restructuring rather than focusing on departures. The promotion of Pirman to lead the internal drug-discovery organization and Car's continued service as an executive officer in a newly created role constitute material executive appointments that would affect investor assessment of the company's scientific leadership structure.
View raw filing on EDGAR →Matthew Toboroff was appointed to the Board of Directors effective July 1, 2026, to fill a vacancy created by the death of Thom Kidrin. The disclosure centers on the appointment action itself. While the filing also mentions a related departure (Kidrin's passing), the principal disclosed action is Toboroff taking a director role. The appointment is material as it affects board composition and involves a related-party relationship (Toboroff's father is the Interim CEO and a Director).
View raw filing on EDGAR →Brad Martin was appointed as Executive Vice President and Chief Information Officer, a named executive officer role at the financial institution. The appointment was made in advance of Tammy Plummer's retirement to ensure a smooth leadership transition.
View raw filing on EDGAR →Greg Lucas accepted an offer to serve as Vice President, Corporate Controller and Chief Accounting Officer, a principal accounting officer role, effective on or before August 10, 2026. While the disclosure includes compensatory details (base salary of $335,000, equity awards, and incentive plan eligibility), the principal disclosed action is the appointment of a named executive to a key accounting and financial reporting role, replacing Agnes Kamps as PAO. This is a material executive appointment.
View raw filing on EDGAR →The filing announces the appointment of Dr. Lance Miller as Technical Advisor to Alaska Silver Corp., a position that brings significant technical expertise to the company's mineral exploration strategy. While the disclosure also mentions Darwin Green's departure from the Technical Committee, the principal action disclosed is the appointment of a new technical advisor with 35+ years of mining experience, making this an executive appointment event. The appointment is material to investors as it signals leadership changes in the company's technical direction for advancing the Illinois Creek project.
View raw filing on EDGAR →GMR Solutions appointed two independent directors, Dr. Amar Desai and Ellen Zane, to its Board of Directors effective July 1, 2026. Both appointees bring substantial healthcare leadership experience and will serve on key board committees.
View raw filing on EDGAR →The filing discloses a leadership transition where Kevin Buchel is appointed to Chief Executive Officer and President, with a salary increase to $900,000 and expanded management responsibilities. While Richard Soloway's role changes from CEO to Executive Chairman (a departure from the CEO position), the principal disclosed action centers on Buchel's appointment to the top executive role. The filing emphasizes Buchel's appointment and his qualifications for the position, making this primarily an appointment event rather than a departure, though both elements are present.
View raw filing on EDGAR →The filing discloses both departures and appointments effective July 3, 2026. Robert Szubanski resigned as Treasurer, Principal Executive Officer, Principal Financial Officer, and Principal Accounting Officer (retaining President role), and Varinia-Rebecca Koenig resigned as Secretary (retaining Board seat). Concurrently, Radek Chovanec was appointed to fill the vacated executive officer roles (Secretary, Treasurer, PEO, PFO, PAO) and elected as a Director. The principal disclosed action centers on the appointment of Chovanec to critical financial and operational leadership positions, making this an exec_appointment event. The material change in control of financial reporting and executive authority supports materiality.
View raw filing on EDGAR →The 6-K discloses the appointment of Mr. Pang Peter Chun Ming as Chief Financial Officer effective July 8, 2026, following the resignation of Mr. Patrick Kwok Fai Lau on the same date. While both a departure and appointment occur, the principal disclosed action is the appointment of a named executive to a C-suite role (CFO), which is material to investors assessing management continuity and financial oversight. The detailed background of the incoming CFO (25+ years experience, CPA, CFA, prior CFO roles at public companies) supports materiality.
View raw filing on EDGAR →HF Sinclair Corp appointed Steven Ledbetter as President and Chief Operating Officer and Valerie Pompa as President, Growth, Technology and Transformation, effective July 6, 2026. Both executives were promoted from Executive Vice President roles, representing a material organizational restructuring at the C-suite level with Franklin Myers remaining CEO but ceding the President title.
View raw filing on EDGAR →The filing discloses the appointment of Jeremy Bender, Ph.D., M.B.A., as a Class II director to Aura Biosciences' Board, effective July 7, 2026. The Board unanimously appointed Dr. Bender to fill a newly created vacancy and assigned him to the Compensation Committee and Nominating and Corporate Governance Committee. This is a clear executive appointment event under Item 5.02, with material significance given Dr. Bender's substantial biotechnology leadership experience and the company's advancement toward regulatory approval of its lead candidate bel-sar.
View raw filing on EDGAR →Jane Pocock, currently CEO of Copart UK, has been appointed to the position of President of Copart, effective August 1, 2026, filling a previously vacant position. The company emphasized her track record leading the UK and Ireland business and her promotion to a global leadership position.
View raw filing on EDGAR →The Board of Directors appointed Darcy Bajko to the position of Chief Commercial Officer effective July 31, 2026, with an annual salary of $315,000, bonus eligibility up to 30%, and a stock option grant of 150,000 shares.
View raw filing on EDGAR →On July 6, 2026, Clemence Rasigni and Christopher Kellen were appointed to the Board of Directors in connection with the IPO, with Ms. Rasigni designated as Audit Committee chair and Mr. Kellen as Compensation Committee chair.
View raw filing on EDGAR →The filing discloses the appointment of Brent Morrison as an independent trustee of Power REIT, effective immediately on July 6, 2026. The Board explicitly states it appointed Morrison to serve until the next annual meeting and highlights his significant executive leadership experience at a publicly traded healthcare company, indicating the Board views his appointment as materially valuable to the Trust's governance and strategic objectives.
View raw filing on EDGAR →The filing discloses the Board of Directors' approval on July 5, 2026, of Mr. John E. Driscoll's appointment as Co-Chief Operating Officer of Blue Chip Capital Group, Inc. The disclosure includes detailed biographical information, professional credentials (CFE, CIA), and extensive experience in corporate finance, accounting, and risk management. This is a clear executive appointment to a senior officer role, making it material to investors' assessment of the company's leadership and operational capacity.
View raw filing on EDGAR →The filing discloses both the departure of Jeffrey Rona as Chief Business and Financial Officer and the appointment of Charles Carter as Chief Financial Officer, effective July 6, 2026. While both events occur, the principal disclosed action centers on Carter's appointment to the CFO role with detailed compensation arrangements (base salary of $460,000, 35% bonus target, 50,000 RSU grant), making exec_appointment the most salient classification. The departure is secondary context to the succession event.
View raw filing on EDGAR →Michael Keogh's appointment as Chief Financial Officer effective August 5, 2026, is the principal disclosed action. While the filing also details his compensation package (base salary of $595,000, 85% target bonus, $2M RSU grant, and severance arrangements), the core event is the appointment of a named executive officer to a C-suite position. The disclosure emphasizes his extensive background at Ford, Apple, Stanley Black & Decker, and Intel, and his role is material to investors assessing the company's leadership and financial management capabilities.
View raw filing on EDGAR →Michael Axelrod was appointed as President and Chief Executive Officer and Board member effective July 29, 2026, following a comprehensive external search. The appointment includes detailed compensation arrangements including a base salary of $1,000,000 and equity awards of $4,750,000, along with severance and change-in-control protections.
View raw filing on EDGAR →The filing discloses the appointment of Charles Weiser as Chief Financial Officer effective July 1, 2026, along with a detailed employment agreement specifying base salary ($225,000), performance bonus (up to 75% of base), signing bonus ($25,000), and equity grants (150,000 options and 125,000 RSUs). While the disclosure includes compensatory arrangements, the principal disclosed action is the appointment of a named executive to a C-suite officer role, making exec_appointment the most salient classification. The appointment of a CFO is material to investors assessing the registrant's financial leadership and governance.
View raw filing on EDGAR →Michael McDonnell was appointed to Moderna's Board of Directors effective July 8, 2026, and simultaneously appointed to the Audit Committee. McDonnell brings extensive CFO experience from major life sciences companies including Biogen and IQVIA.
View raw filing on EDGAR →The 6-K discloses the appointment of two new directors effective July 1, 2026: Ruobai Sima (the Company's existing CFO since May 2022) and Han Jiang (an external candidate with art and design expertise). While the report also discloses two director departures (Jun Zhang and Andrew Y. Yan, both citing personal reasons), the principal disclosed action is the appointment of new board members. The appointment of the CFO to the board and the addition of a new independent director are material governance changes affecting board composition and oversight.
View raw filing on EDGAR →Muhammad Asif Seemab was appointed President and Interim Chief Executive Officer effective July 6, 2026, following the concurrent resignation of Muhammad Umair from the CEO role.
View raw filing on EDGAR →The filing discloses two executive changes at the Manager: the retirement of Brian Douglas as CEO and the promotion of Jason Slutsky to Chief Operating Officer and General Counsel effective June 26, 2026. While both a departure and an appointment occur, the prose centers on Slutsky's promotion to a senior operational role with expanded responsibilities overseeing legal, compliance, technology, trading, administration, and human resources. The detailed biographical and compensation information provided for Slutsky (age, education, tenure, salary eligibility, post-employment obligations) emphasizes the appointment as the principal disclosed action, making this an exec_appointment event.
View raw filing on EDGAR →The filing discloses two executive changes at the Manager: the retirement of Brian Douglas as CEO and the promotion of Jason Slutsky to Chief Operating Officer and General Counsel effective June 26, 2026. While both a departure and an appointment occur, the filing's primary focus and detailed disclosure center on Slutsky's appointment to the COO role, including his background, responsibilities, and compensation terms. The appointment of a COO to lead critical operational functions (legal, compliance, technology, trading services, administration, HR) is material to investors' assessment of the fund's management and governance.
View raw filing on EDGAR →The press release announces the appointment of three industry leaders—Robert Bazemore, Amy Pott, and Dr. Helen Thackray—to Eupraxia's Board of Directors. Each appointee brings substantial experience in drug development, commercialization, and clinical leadership. The CEO explicitly states their expertise will be "invaluable as we execute on several key upcoming milestones," indicating material governance strengthening at a pivotal stage for the company.
View raw filing on EDGAR →The disclosure centers on the appointment of Karen Fascenda as Chief Human Resources Officer effective July 6, 2026, succeeding Novelette Murray who retired the same day. While both a departure and appointment occur, the press release and Item 8.01 disclosure emphasize the appointment of the new CHRO with detailed background on her qualifications and experience, making exec_appointment the principal event. The CHRO is a named executive officer role, and the appointment of a successor to a C-suite position is material to investors assessing leadership continuity and human capital strategy.
View raw filing on EDGAR →The filing discloses the appointment of Mr. Choi, Hoe-Yong as a non-standing director of KEPCO, effective July 7, 2026, for a two-year term, replacing former director Mr. Kang, Hoon. This is a clear executive/director appointment event. While non-standing directors may have limited operational authority, director appointments at a major utility company are material to investors' assessment of governance and board composition.
View raw filing on EDGAR →The filing discloses the Board's determination on June 30, 2026 to appoint Gregory R. Allen to fill an open vacancy on the Board of Directors, with his first meeting scheduled for September 29, 2026. While the disclosure includes standard board compensation details and related-party transaction disclosures, the principal action is the appointment of a director to the Board. This is a material governance event affecting the composition of the registrant's board.
View raw filing on EDGAR →Andrew Gelb and Srini Krish were appointed as interim leaders of Fiserv's Financial Solutions business effective July 7, 2026, following the departure of the President.
View raw filing on EDGAR →The filing discloses both a director resignation (Dr. Levin) and a director appointment (Dr. Zaccardelli). While both events are present, the principal disclosed action centers on the appointment of David Zaccardelli, Pharm.D. as a director on July 7, 2026, with detailed disclosure of his qualifications, compensation arrangements (annual cash retainer of $40,000 and equity grants), and board service terms. The appointment is material as it involves a change in board composition and compensation commitments.
View raw filing on EDGAR →The filing discloses the appointment of Evgeny Zaytsev, M.D., Ph.D. as a Class I director effective immediately, with the Board increasing from seven to eight directors. While the section also mentions Fred Middleton's retirement, the principal disclosed action centers on the new director appointment. The appointment includes standard director compensation (annual cash retainer of $40,000 and a 20,000-share option grant vesting over three years), which is material to investors assessing board composition and governance.
View raw filing on EDGAR →The disclosure centers on the appointment of three new directors (Thurman Justice, Lori Goltermann, and Safwan Shabab) to the Board on July 2, 2026, with specified committee assignments and equity grants. While Jeffrey Rhodes' resignation is also mentioned, it is explicitly stated as not resulting from disagreement and is presented as the context for filling vacancies. The principal disclosed action is the appointment of three directors, making exec_appointment the most salient classification.
View raw filing on EDGAR →T-Mobile appointed Chris Sambar as Chief Enterprise Officer, effective no later than October 14, 2026, reporting directly to CEO Srini Gopalan. The appointment represents a material C-suite leadership change to lead the company's enterprise and government businesses.
View raw filing on EDGAR →Manuel Benito Miranda was appointed as a Class II director effective June 30, 2026, filling a vacancy created by an increase in board size from 8 to 9 directors, and was also appointed to the Compensation Committee.
View raw filing on EDGAR →The filing discloses the appointment of Donn Casale as Chief Executive Officer effective immediately and his concurrent appointment to the Board as a Class III director. While the section also mentions Richard Lowenthal's termination without cause, the principal disclosed action centers on Casale's elevation to CEO and board appointment, making this an exec_appointment event. This is material as it represents a change in the company's principal executive officer.
View raw filing on EDGAR →SunPower Inc. appointed Tom Kowalczuk as Chief Financial Officer and Principal Financial Officer effective June 30, 2026. The filing discloses his background, compensation terms ($400,000 base salary, 50% target bonus), and a material equity grant of 1,000,000 RSUs with specified vesting schedules. This is a principal executive appointment material to investors assessing the company's financial leadership.
View raw filing on EDGAR →